Form 4 AMGEN INC For: Apr 30 Filed by: Gordon Murdo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Amgen (AMGN) PT Raised to $307 at UBS
May 3, 2024 7:06 AM EDTUBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $307.00 (from $284.00) while maintaining a Neutral rating.
The analyst comments "The much anticipated MariTide interim completed (earlier than we expected) with mgmt providing positive qualitative commentary, as we had expected. At face... More
Amgen (AMGN) PT Lowered to $328 at RBC Capital
May 3, 2024 6:35 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Amgen (NASDAQ: AMGN) to $328.00 (from $332.00) while maintaining a Outperform rating.
The analyst comments "GLP-1/GIPR, MariTides stated success on the ph.II interim data look internally takes the cake on the call,... More
Goldman Sachs Comments on Amgen (AMGN)
May 3, 2024 5:53 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Conviction Buy rating and $350.00 price target on Amgen (NASDAQ: AMGN)
The analyst comments "AMGN reported 1Q earnings (in-line top- and bottom-line; details within), with shares trading up significantly post-market (+15%; adding ~$20bn in market cap) as management provided a positive high-level interim update from the ongoing Ph2 study for MariTide in obesity, noting: (1) a differentiated profile vs. currently available therapies (e.g., LLYs Zepbound and NVOs Wegovy), as well as those in clinical development, (2) plans to rapidly advance a broad... More
